Recursion Pharmaceuticals, Inc.

NasdaqGS:RXRX Stok Raporu

Piyasa değeri: US$1.8b

Recursion Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Chris Gibson

İcra Kurulu Başkanı

US$8.6m

Toplam tazminat

CEO maaş yüzdesi6.5%
CEO görev süresi11yrs
CEO sahipliği2.6%
Yönetim ortalama görev süresi3.6yrs
Yönetim Kurulu ortalama görev süresi10.2yrs

Son yönetim güncellemeleri

Recent updates

Recursion: AI Is Only As Good As The Data

Sep 11

Recursion: Path Forward For REC-994 Remains Despite Mixed Response

Sep 04

Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 12
Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Recursion Pharmaceuticals: AI-Driven 'TechBio' With Upcoming Catalysts

Aug 01

Recursion Pharmaceuticals: More Of A TechBio Industrializing Drug Discovery

Jun 24

Recursion Pharmaceuticals: Catalysts Are Coming And Success Is A Must

Jun 14

Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%

May 22
Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 12
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate

Apr 10

Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade)

Mar 20

Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely

Jan 31
Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely

Recursion Pharmaceuticals: More Hype Than Substance Amid Signs Of Progress

Jan 12

Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues

Dec 09
Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues

What You Need To Know About The Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analyst Downgrade Today

May 09
What You Need To Know About The Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analyst Downgrade Today

We Think Recursion Pharmaceuticals (NASDAQ:RXRX) Can Easily Afford To Drive Business Growth

Mar 01
We Think Recursion Pharmaceuticals (NASDAQ:RXRX) Can Easily Afford To Drive Business Growth

CEO Tazminat Analizi

Chris Gibson'un ücretlendirmesi Recursion Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$375m

Mar 31 2024n/an/a

-US$354m

Dec 31 2023US$9mUS$561k

-US$328m

Sep 30 2023n/an/a

-US$293m

Jun 30 2023n/an/a

-US$260m

Mar 31 2023n/an/a

-US$249m

Dec 31 2022US$6mUS$498k

-US$239m

Sep 30 2022n/an/a

-US$247m

Jun 30 2022n/an/a

-US$234m

Mar 31 2022n/an/a

-US$212m

Dec 31 2021US$674kUS$485k

-US$186m

Sep 30 2021n/an/a

-US$147m

Jun 30 2021n/an/a

-US$124m

Mar 31 2021n/an/a

-US$99m

Dec 31 2020US$3mUS$270k

-US$87m

Tazminat ve Piyasa: Chris 'nin toplam tazminatı ($USD 8.61M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 5.64M ).

Tazminat ve Kazançlar: Chris şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Chris Gibson (41 yo)

11yrs

Görev süresi

US$8,613,208

Tazminat

Dr. Christopher C. Gibson, also known as, Chris, Ph.D. is a Co-Founder of Recursion Pharmaceuticals Inc and serves as its Chief Executive Officer and Director since November 2013. Previously, Dr. Gibson wa...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Christopher Gibson
Co-Founder11yrsUS$8.61m2.55%
$ 45.9m
Tina Larson
COO & President6.3yrsUS$4.87m0.057%
$ 1.0m
Blake Borgeson
Co-Founder & Director11.8yrsUS$292.74k2.51%
$ 45.2m
Michael Secora
Chief Financial Officer4.7yrsUS$4.51m0.41%
$ 7.4m
David Mauro
Chief Medical Officer1.4yrsUS$4.53m0.015%
$ 275.5k
Kevin Leggat
Vice President of Finance & Accountingno dataVeri yokVeri yok
Benjamin Mabey
Chief Technology Officer4.8yrsVeri yokVeri yok
Jared Allenbach
Senior Director of Investor Relations2.5yrsVeri yokVeri yok
Nathan Hatfield
Chief Legal Officer & General Counsel1.1yrsVeri yokVeri yok
Ryan Kelly
Chief Communications Officer2.5yrsVeri yokVeri yok
Matthew Kinn
Chief Corporate Development Officer and SVP of Business Development & Corporate Initiativesless than a yearVeri yokVeri yok
Janelle Gordon
Vice President of People Operationsno dataVeri yokVeri yok

3.6yrs

Ortalama Görev Süresi

41.5yo

Ortalama Yaş

Deneyimli Yönetim: RXRX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.6 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Christopher Gibson
Co-Founder11yrsUS$8.61m2.55%
$ 45.9m
Blake Borgeson
Co-Founder & Director11.8yrsUS$292.74k2.51%
$ 45.2m
Najat Khan
Chief R&D Officerless than a yearVeri yokVeri yok
Robert Lollini
Member of Business Advisory Panel10yrsVeri yokVeri yok
H. Fell
Member of Business Advisory Panel10.4yrsVeri yokVeri yok
Joseph Miletich
Chairman of Therapeutics Advisory Board3.3yrsVeri yokVeri yok
Robert Hershberg
Independent Chairman4.7yrsUS$302.74k0.014%
$ 247.1k
Dean Li
Co-Founder & Independent Director11yrsUS$300.25k1.13%
$ 20.3m
Zachary Bogue
Independent Director6.3yrsUS$21.25k0.0033%
$ 60.1k
Anne Carpenter
Member of Scientific and Technical Advisory Board10.6yrsVeri yokVeri yok
Kirk Thomas
Member of Scientific & Technical Advisory Board10.6yrsVeri yokVeri yok
Zavain Dar
Independent Director8.2yrsUS$307.74k0.033%
$ 596.1k

10.2yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: RXRX 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 10.2 yıldır).